We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Experimental Drug Slows Lung Cancer Growth by Blocking Protein Glycosylation

By LabMedica International staff writers
Posted on 03 Nov 2016
Print article
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).
An interesting new experimental anti-cancer drug slows growth of certain lung tumor cells by preventing the glycosylation of critical cell surface receptor proteins.

Asparagine (N)-linked glycosylation is a protein modification process that is critical for glycoprotein folding, stability, and cellular localization. To identify small molecules that would inhibit new targets in this biosynthetic pathway, investigators at Yale University (New Haven, CT, USA) and colleagues at several other institutions initiated a cell-based high-throughput screen and lead-compound-optimization campaign. During this campaign the researchers screened more than 350,000 chemical compounds while searching for those that could partially disrupt glycosylation. The result was the small molecule cell-permeable inhibitor NGI-1.

The investigators reported in the October 3, 2016, online edition of the journal Nature Chemical Biology that NGI-1 targeted oligosaccharyltransferase (OST), a hetero-oligomeric enzyme that exists in multiple isoforms and transfers oligosaccharides to recipient proteins.

In non-small-cell lung cancer (NSCLC) cells, NGI-1 blocked cell-surface localization and signaling of the epidermal growth factor receptor (EGFR) glycoprotein, but selectively arrested proliferation in only those cell lines that were dependent on EGFR (or fibroblast growth factor, FGFR) for survival. In these cell lines, OST inhibition caused cell-cycle arrest accompanied by cell morphology changes that were hallmarks of senescence.

“This is important to cancer research because what we are looking for are therapies that do not have a lot of effect on normal cells but do have a lot of effect on tumor cells, and this falls into that category,” said senior author Dr. Joseph Contessa, associate professor of therapeutic radiology and of pharmacology at Yale University. “We have therapies, and they are good therapies, but they are not enough. We need to take the next step.”

Related Links:
Yale University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Ultrasound-based duplex sonography combined with a new genetic testing procedure can identify clonal haematopoiesis (Photo courtesy of 123RF)

New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk

A key interest area in cardiovascular research today is the impact of clonal hematopoiesis on cardiovascular diseases. Clonal hematopoiesis results from mutations in hematopoietic stem cells and may lead... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.